SCHEMBL5592576

SCHEMBL5592576

COc1ccc(Cl)cc1NC(=O)Nc1cccc2c1ccn2Cc1ccnc(NS(C)(=O)=O)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
POLB P06746 2/20 0.46
MAPT P10636 2/20 0.43
EPHB4 P54760 3/20 0.43
IGF1R P08069 3/20 0.43
HCK P08631 1/20 0.41
MAPK12 P53778 1/20 0.41
MAPK14 Q16539 1/20 0.41
NTRK1 P04629 1/20 0.41
NTRK2 Q16620 1/20 0.41
KDM4E B2RXH2 2/20 0.41
NR3C2 P08235 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.40
ALOX12 P18054 1/20 0.40
TP53 P04637 1/20 0.40
NR3C1 P04150 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5592629 0.91 EPHB4 (0.43) MEN1KMT2AMAPTEPHB4HCK
SCHEMBL5585966 0.90 MEN1 (0.48) MEN1KMT2APOLBMAPTEPHB4
Cyclopropane SCHEMBL9108474 0.88 MEN1 (0.46) MEN1KMT2APOLBMAPTEPHB4
SCHEMBL9885353 0.87 MEN1 (0.45) MEN1KMT2APOLBMAPTEPHB4
SCHEMBL5959777 0.87 MEN1 (0.45) MEN1KMT2APOLBMAPTEPHB4
SCHEMBL5600303 0.87 MEN1 (0.45) MEN1KMT2APOLBMAPTEPHB4
SCHEMBL5959883 0.86 MEN1 (0.43) MEN1KMT2APOLBMAPTEPHB4
SCHEMBL5959896 0.86 MEN1 (0.46) MEN1KMT2APOLBMAPTEPHB4
SCHEMBL5592585 0.86 MEN1 (0.47) MEN1KMT2APOLBMAPTEPHB4
SCHEMBL5600048 0.86 MEN1 (0.57) MEN1KMT2APOLBMAPTEPHB4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP claimed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP claimed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US claimed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO claimed
EP-1858879-B1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY GILEAD CONNECTICUT INC (US) 2012-06-06 EP disclosed
EP-2397478-A1 1,3-diaryl substituted ureas as modulators of kinase activity. CGI Pharmaceuticals, Inc. (US) 2011-12-21 EP disclosed
EP-1858879-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI Pharmaceuticals, Inc. (US) 2007-11-28 EP disclosed
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity GILEAD CONNECTICUT, INC. 2006-09-07 US disclosed
WO-2006076593-A1 1,3-DIARYL SUBSTITUTED UREAS AS MODULATORS OF KINASE ACTIVITY CGI PHARMACEUTICALS, INC. (US) 2006-07-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199846-A1 Certain substituted ureas as modulators of kinase activity UCK2, CHUK, AXL MEN1 3417/4885KMT2A 3501/4885POLB 3113/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.